Stereotaxis Shares Advance on FDA Approval for Magnetic Catheter
By Elias Schisgall
Shares of Stereotaxis advanced after the company said it received Food and Drug Administration approval for its Magnetic Interventional Ablation Catheter product.
The stock as up 14% to $2.70 in Tuesday morning trading. Shares have risen 3.6% in the past year.
The surgical robot company said the FDA had greenlit the product, which uses robotic magnet technology to perform cardiac ablation procedures to treat heart arrhythmia.
"FDA approval of MAGiC is a significant milestone for Stereotaxis and the community of physicians pioneering robotics in electrophysiology," Chief Executive Officer David Fischel said Tuesday.
"It ensures the benefits of Robotic Magnetic Navigation can support patients with complex and critical heart rhythm disorders, represents a major advance in robotic cardiac ablation technology, and provides a foundation for continued technological and clinical progress," he added.
Write to Elias Schisgall at elias.schisgall@wsj.com
(END) Dow Jones Newswires
January 06, 2026 10:12 ET (15:12 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States